Proactive Investors - Finance
24 Jul 2026, 10:37 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Actinogen Medical's Phase 2 trial of Xanamem showed statistically significant antidepressant activity in patients with difficult-to-treat major depressive disorder. — Positive clinical trial results for a lead candidate in a high-unmet-need market typically drive significant valuation increases for biotech companies.
+0.60Topline results for the pivotal XanaMIA Phase 2b/3 study for Alzheimer's disease are expected in November 2026. — This establishes a concrete catalyst date for the company's primary development program, creating a timeline for potential volatility.
+0.40Xanamem provided no evidence of cognitive benefit over the placebo in the major depressive disorder trial. — Failure to show cognitive improvement is a negative signal, though tempered by the trial's primary focus on antidepressant activity.
-0.30Continue reading
6 related stories
Search tags
Further antidepressant trials for Xanamem are contingent upon securing future funding and partnership arrangements. — Indicates a dependency on external capital or partners to progress this specific indication, introducing financial execution risk.
-0.20Which stocks this story touches
The company reported encouraging Phase 2 trial results showing clinically meaningful antidepressant activity for its lead drug candidate Xanamem.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
1d ago
